SOMATIC VARIANT ANALYSIS REQUEST FORM
(NGS based tests for targeted therapy stratification*)

Sarah Cannon Molecular Diagnostics, Ground Floor, Shropshire House, 1 Capper Street, London WC1E 6JA UK. Tel: +44 (0)203 794 1920

*Please note: Whilst much more comprehensive, these assays will have longer turnaround times that our more limited non-NGS based tests. Please consider appropriate clinical needs when choosing.

SARAH CANNON
Molecular Diagnostics

Part of HCA Healthcare UK

Web: www.sarahcannon-md.co.uk
Email: info@sarahcannon-md.co.uk

FOR LABORATORY USE ONLY			
SCMD No:	**Received by:**	**Prepared by:**	**Received:** (Date/Time)

INDIVIDUAL AUTHORISING REQUEST (e.g. Clinician / Pathologist)	
Name:	**Address:**
Phone:	

DESTINATION FOR ANALYSIS REPORT (ESSENTIAL – Results may be delayed if not completed)	
Name:	**Address:**
Phone:	**Note: If as above please tick here** ☐

Required Method(s) for Report Delivery *(please tick all that apply)*: **Post** ☐ **Fax** ☐ **Email** ☐

Results Fax number(s):	**Results e-mail(s):**

INVOICING DETAILS (ESSENTIAL – Results may be delayed if not completed in full)	
Contact name:	**Full Organisation Name and Postal Address:**
Phone:	
Email:	**Note: An authorisation code is mandatory if providing private medical insurance details**

PATIENT DETAILS (At least 3 unique identifiers are mandatory)			
Surname:	**Forename:**	**DOB** *(DD/MM/YY)*:	**Sex:** **M** ☐ **F** ☐

Hospital Name:	**Surgical Case ID:**	**Hospital Number:**	**Requester Ref (if applicable):**

SAMPLE / PATHOLOGY DETAILS (Please provide as much information as possible)

Material Supplied: *(see website for tissue requirements)*		**Estimated % of tumour nuclei (required for curls/DNA)**	
FFPE Block ☐	**Unstained Slides** ☐	**5-20%** ☐	**51-75%** ☐
Sections 'curls' ☐	**Other:**_____ ☐	**21-50%** ☐	**>75%** ☐

Primary Tumour Type: e.g. Lung	**Tumour Subtype:** e.g. Adenocarcinoma	**Tissue Supplied:** e.g. Liver

Address for return of FFPE block or other unused material:

Note: If left blank, material will be returned to the same address as specified for the analysis report.

ANALYSIS REQUIRED (See website for full details of each assay)

MGP-4 DNA (Small variant/CNG panel) ☐	**MGP-4 RNA (Fusion panel)** ☐	**Reflex test DNA > RNA**
Analysis of 'Hotspot' SNVs & small indels in: AKT1, ALK, BRAF, CCNE1, CDK4/6, CDKN2A, CTNNB1, CXCR4, EGFR, ERBB2, ESR1, FBXW7, FGFR1/2/3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MAP2K1, MET, MTOR, MYD88, NRAS, NTRK1/3, PDGFRA, PIK3CA, POLD1, POLE, PTEN, RET, ROS1, SMAD4, STK11, TP53. Includes analysis of CNGs (copy number gains >2 fold in samples with >20% tumour) in: EGFR, ERBB2, KRAS, KIT, MET, PIK3CA.	Analysis of inter-/intragenic rearrangements (fusions) in: ALK, BRAF, EGFR, MET, NTRK1/3, RET, and ROS1. Please note that other gene fusions are included but are currently designated RUO.	Reflex to NGS-based gene fusion panel (can reduce cost but will increase turnaround time). ☐ Reflex to rapid PCR based Lung fusion panel: ALK, ROS1, RET & MET exon 14 skipping (can reduce cost without excessive delay, but limited scope and restricted to NSCLC only). ☐